Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Language
Clinical aspect
Year range
1.
International Immunopharmacology ; 2020.
Article | WHO COVID | ID: covidwho-689157

ABSTRACT

Corona Virus Disease 2019 (COVID-19) has spread rapidly to more than 215 countries, with over 11 91 million reported cases and more than 540,000 deaths Rapid diagnosis remains a bottleneck for containing the epidemic We used an automated chemiluminescent immunoassay to detect serum IgM and IgG antibodies to the 2019-nCoV in 742 subjects, so as to observe the dynamic process of antibody production in COVID-19 disease and seroepidemiology in different populations Patients with COVID-19 were reactive (positive) for specific antibodies within 3-15 days after onset of symptoms Specific IgM and IgG levels increased with the progression of the disease The areas under the receiver operating characteristic curves for IgM and IgG were 0 984 and 1 000, respectively This antibody detection assay had good sensitivity and specificity The understanding of the dynamic serological changes of COVID-19 patients and the seroepidemiological situation of the population will be helpful to further control the epidemic of COVID-19

2.
J. Inflamm. ; 1(17)20200514.
Article in English | ELSEVIER | ID: covidwho-260363

ABSTRACT

Background: To investigate the efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia. Methods: One hundred sixty-four patients with noninfluenza viral pneumonia were divided into IFNα1b and control groups. The IFNα1b group received routine treatment + aerosol inhalation of recombinant human IFNα1b injection (50 μg × 2 injections, bid). The control group received routine treatment + IFN analog (two injections, bid). Overall response rate (ORR) of five kinds clinical symptoms. Further outcomes were daily average score and the response rate of each of the symptoms above. Results: A total of 163 patients were included in the full analysis set (FAS) and 151 patients were included in the per-protocol set (PPS). After 7 days of treatment, ORR of clinical symptoms was higher in IFNα1b group than that in control group for both the FAS and PPS. Moreover, after 7 days of treatment, the daily score of three efficacy indexes including expectoration, respiratory rate, and pulmonary rales were improved. The ORRs for expectoration and pulmonary rales were higher in the IFNα1b group than in the control group (P < 0.05). There were no significant differences of the ORRs for coughing, chest pain and respiratory rate between the two groups (P > 0.05). The incidence of adverse events was 6.5% (n = 5) in IFNα1b group and 3.5% (n = 3) in control group (P > 0.05). Conclusion: Aerosol inhalation of recombinant human IFNα1b is safe and it can improve the clinical symptoms of noninfluenza viral pneumonia.

SELECTION OF CITATIONS
SEARCH DETAIL